What the approvals tracker records
Alternative proteins reach the market through food-safety systems that differ sharply by country. A precision-fermentation protein, a cultivated meat cell line and a mycoprotein flour can each follow a different route, with different evidence requirements and different outcomes. The table on this page records those decisions in one place so buyers and developers can compare status across jurisdictions.
Each row names the product or ingredient, the regulator, the type of decision, the instrument that carries it and the date. Every row links to the regulator's own record, such as an opinion, a regulation, a notice inventory entry or a register listing. Where a decision has conditions, such as restricted uses or labelling, the row says so briefly.
European Union novel food authorisations
In the European Union a novel food is one not consumed to a significant degree by humans in the Union before 15 May 1997. Such foods need authorisation before they are placed on the market. The applicant submits a dossier, the European Food Safety Authority assesses safety, and the Commission and Member States then decide whether the food is authorised.
EFSA has nine months to complete its risk assessment, and the clock stops whenever it asks the applicant for more data. After the opinion, the Commission consults Member State authorities, and an authorisation takes the form of an implementing regulation that amends the Union list of novel foods. The list states permitted uses, maximum levels and labelling for each entry.
An authorisation lists the food together with its specification, permitted uses and labelling conditions. The EFSA opinion and the later regulation are separate events, often months apart, and the gap matters commercially because a favourable opinion alone does not allow sales. The tracker therefore records both events as separate rows, each with its own date and link.
United States: FDA GRAS notices and cultivated meat
In the United States, many ingredients enter food through the generally recognised as safe pathway. A company may conclude on its own that an ingredient is GRAS for its intended use, and may voluntarily notify the Food and Drug Administration. The agency publishes each notice in its GRAS Notice Inventory together with the response letter it sent.
A "no questions" letter means the agency did not question the notifier's conclusion for the stated conditions of use. It is not a formal approval and does not list the ingredient in a regulation. Other responses exist, including letters that find the basis insufficient and notices withdrawn by the notifier, and the tracker marks those outcomes plainly.
Cultivated meat follows a different path. FDA describes a voluntary pre-market consultation that evaluates cell lines, cell banks, manufacturing controls and inputs. For livestock and poultry, the Food Safety and Inspection Service of USDA then oversees harvest. Establishments need a USDA grant of inspection, and all labelling of such products must be preapproved by the service.
Singapore, Australia and New Zealand, and Israel
Singapore treats as novel any food or ingredient without a history of use as food over the past 20 years, including substances from cell or tissue culture. Such foods need Singapore Food Agency pre-market approval before supply. Applicants provide safety assessments backed by scientific evidence, and the agency can cancel an approval if conditions are breached or information changes.
In Australia and New Zealand, novel foods are assessed by FSANZ, which amends the Food Standards Code when an application succeeds. A novel food cannot be sold at retail unless it is listed in the table to the relevant section of Standard 1.5.1. Applicants may request a period of exclusive use of up to 15 months.
Israel is tracked as its own market. The Ministry of Health handles novel food applications, and the table records its No Questions letter for cultivated beef from Aleph Farms in January 2024, issued with labelling conditions. Because dossiers and published records differ by country, each entry links to the most direct source available, so readers can check the wording.
How to read the table, and what an approval does not mean
Read the table from left to right: product, regulator, decision type, instrument, date and conditions. Filter by region when sourcing for a specific market, because an approval in one country gives no right to sell in another. Compare the decision type carefully, since an EFSA opinion, a Union list entry and a GRAS letter carry very different legal weight.
An approval is a safety and legality finding for a defined product under stated conditions. It does not say the ingredient tastes acceptable, performs in a given matrix, is available in volume or is priced competitively. It also does not cover a changed process, a different strain or a new use outside the listed conditions, which usually need fresh assessment.
Entries are added when a primary record appears and corrected when the regulator amends or withdraws its decision. The review date on this page shows when the table was last checked against the sources. Buyers should still confirm current status with the regulator's own register before signing a supply contract or launching a product.